Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intraperitoneal carboplatin: rationale and experience.

J L Speyer1, J Sorich

  • 1Division of Oncology, Rita and Stanley H. Kaplan Cancer Center, New York University Medical Center, NY 10016.

Seminars in Oncology
|February 1, 1992
PubMed
Summary

Intraperitoneal carboplatin shows promise for advanced gynecologic cancers. Recommended starting doses vary based on renal function, with myelosuppression as the main toxicity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Robust control for convection suppression in a fluid layer: The effects of boundary properties, actuator lag, and major parameter uncertainties.

Physical review. E, Statistical, nonlinear, and soft matter physics·2006
Same author

Gain-scheduled controller for the suppression of convection at high Rayleigh number.

Physical review. E, Statistical, nonlinear, and soft matter physics·2005
Same author

Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival.

Human pathology·2001
Same author

Intraperitoneal topoisomerase-I inhibitors. Preliminary findings with 9-aminocamptothecin.

Annals of the New York Academy of Sciences·2001
Same author

Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1999
Same author

A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin chemotherapy in patients with advanced epithelial ovarian cancer.

Gynecologic oncology·1999

Area of Science:

  • Oncology
  • Pharmacology
  • Gynecologic Oncology

Background:

  • Carboplatin exhibits known activity in ovarian cancer.
  • Intraperitoneal (IP) administration may offer a favorable drug exposure ratio.
  • Patients often have extensive prior treatment, including cisplatin.

Purpose of the Study:

  • To evaluate the safety and tolerability of IP carboplatin in advanced gynecologic malignancies.
  • To determine dose-escalation parameters and dose-limiting toxicities.
  • To assess the efficacy of IP carboplatin in heavily pretreated patients.

Main Methods:

  • Phase I/II clinical trial involving 27 patients.
  • Dose escalation of IP carboplatin from 200 mg/m2 to 500 mg/m2.
  • Dosage adjustments based on renal function (creatinine clearance).

Main Results:

  • Myelosuppression, particularly thrombocytopenia, was the dose-limiting toxicity.
  • Recommended starting dose of 400 mg/m2 for pretreated patients.
  • Lower starting dose of 200 mg/m2 for patients with creatinine clearance 30-60 mL/min.
  • Eight patients experienced over 2 years of disease progression-free survival.

Conclusions:

  • IP carboplatin is a potential treatment option for advanced gynecologic malignancies.
  • Specific dosing recommendations are provided based on patient's renal function.
  • Further investigation of IP carboplatin in clinical trials is warranted.

Related Experiment Videos